Bowley Erin, Mulvihill Erin, Howard Jeffrey C, Pak Brian J, Gan Bing Siang, O'Gorman David B
Cell and Molecular Biology Laboratory, Hand and Upper Limb Centre, Lawson Health Research Institute, St. Joseph's Health Centre, London, Ontario, Canada.
BMC Biochem. 2005 Dec 16;6:29. doi: 10.1186/1471-2091-6-29.
As a component of the progression from genomic to proteomic analysis, there is a need for accurate assessment of protein post-translational modifications such as phosphorylation. Traditional kinase assays rely heavily on the incorporation of gamma-P32 radiolabeled isotopes, monoclonal anti-phospho-protein antibodies, or gel shift analysis of substrate proteins. In addition to the expensive and time consuming nature of these methods, the use of radio-ligands imposes restrictions based on the half-life of the radionucleotides and pose potential health risks to researchers. With the shortcomings of traditional assays in mind, the aim of this study was to develop a high throughput, non-radioactive kinase assay for screening Glycogen Synthase Kinase-3beta (GSK-3beta) activity.
Synthetic peptide substrates designed with a GSK-3beta phosphorylation site were assayed with both recombinant enzyme and GSK-3beta immunoprecipitated from NIH 3T3 fibroblasts. A molecular weight shift equal to that of a single phosphate group (80 Da.) was detected by surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) in a GSK-3beta target peptide (2B-Sp). Not only was there a dose-dependent response in molecular weight shift to the amount of recombinant GSK-3beta used in this assay, this shift was also inhibited by lithium chloride (LiCl), in a dose-dependent manner.
We present here a novel method to sensitively measure peptide phosphorylation by GSK-3beta that, due to the incorporation of substrate controls, is applicable to either purified enzyme or cell extracts. Future studies using this method have the potential to elucidate the activity of GSK-3beta in vivo, and to screen enzyme activity in relation to a variety of GSK-3beta related disorders.
作为从基因组分析向蛋白质组分析发展进程的一个组成部分,准确评估蛋白质翻译后修饰(如磷酸化)很有必要。传统的激酶测定法严重依赖于γ-P32放射性标记同位素的掺入、单克隆抗磷酸化蛋白抗体或底物蛋白的凝胶迁移分析。除了这些方法成本高且耗时外,放射性配体的使用还基于放射性核苷酸的半衰期带来限制,并对研究人员构成潜在健康风险。考虑到传统测定法的缺点,本研究的目的是开发一种用于筛选糖原合酶激酶-3β(GSK-3β)活性的高通量、非放射性激酶测定法。
用从NIH 3T3成纤维细胞免疫沉淀的重组酶和GSK-3β对设计有GSK-3β磷酸化位点的合成肽底物进行了测定。通过表面增强激光解吸/电离飞行时间质谱(SELDI-TOF-MS)在GSK-3β靶肽(2B-Sp)中检测到了与单个磷酸基团(80 Da)相等的分子量变化。该测定中分子量变化不仅对所用重组GSK-3β的量呈剂量依赖性反应,而且这种变化也被氯化锂(LiCl)以剂量依赖性方式抑制。
我们在此提出一种灵敏测量GSK-3β介导的肽磷酸化的新方法,由于纳入了底物对照,该方法适用于纯化酶或细胞提取物。使用这种方法的未来研究有潜力阐明GSK-3β在体内的活性,并筛选与多种GSK-3β相关疾病有关的酶活性。